A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with.

Slides:

Advertisements

Similar presentations

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

Advertisements

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation Sarah J. Kizilbash, Clifford E. Kashtan,

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Improvement of Disease Status Determination and Documentation Pre- and Post- Transplant Michelle Bycko, Crystal Gazaway, Jennifer Holter Chakrabarty,

How to Treat MDS without Stem Cell Transplantation

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation David Stephen Shulman, Wendy B. London, Dongjing.

Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report Ivana N.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Temporal Changes in Plerixafor Administration and Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial in Multiple Myeloma

Recovery and Safety Profiles of Marrow and PBSC Donors: Experience of the National Marrow Donor Program John P. Miller, Elizabeth H. Perry, Thomas H.

Immune Reconstitution after Autologous Hematopoietic Cell Transplant (AHCT) in B-Cell Non-Hodgkin Lymphoma (B-NHL) Patients Mobilized with Granulocyte.

Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G- CSF and Plerixafor Compared to G-CSF and Cyclophosphamide Paul Shaughnessy,

Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis.

Sabina Kersting, Leo F. Verdonck

Homeostatic γδ T Cell Contents Are Preserved by Granulocyte Colony-Stimulating Factor Priming and Correlate with the Early Recovery of γδ T Cell Subsets.

Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation Iskra Pusic, Shi Yuan Jiang,

The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation

Mobilization of Hematopoietic Progenitors from Normal Donors Using the Combination of Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte.

Treatment with Plerixafor in non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation Jessica T. Stover,

High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients.

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Recombinant Human Granulocyte Colony-Stimulating Factor Significantly Decreases the Expression of CXCR3 and CCR6 on T Cells and Preferentially Induces.

Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma Peter Dreger, Ginna.

Paul Szabolcs, Donna Niedzwiecki

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic.

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Factors Associated with Peripheral Blood Stem Cell Yield in Volunteer Donors Mobilized with Granulocyte Colony-Stimulating Factors: The Impact of Donor.

B Cells and Transplantation: An Educational Resource

Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients LeAnne Kennedy, Marie Cavalier,

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Incidence of Post-Transplant Bacterial Foodborne Pathogens in Hematopoietic Stem Cell Transplant Patients Nicole Boyle, Sara Podczervinski, Kim Jordan,

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Early Results of Phase II Study Using OMS721 in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HCT-TMA) Samer.

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation Sarah J. Kizilbash, Clifford E. Kashtan,

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis Jason.

Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia Yu Wang,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pauline Damien, David S. Allan

ASBMT and CBMTG Release Choosing Wisely BMT Recommendations

Guidance for Developing Phase II Cell Therapy Trial Proposals for Consideration by the Blood and Marrow Transplant Clinical Trials Network Edwin M. Horwitz,

Gerard Socié, K. Scott Baker, Smita Bhatia

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation Mohammed M. Elayan, Justin G.

What is quality in a transplant program?

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Richard Mitchell, John E. Wagner, Claudio G

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Improving the Informed Consent Process in Hematopoietic Cell Transplantation: Patient, Caregiver, and Provider Perspectives Minakshi Raj, Sung Won Choi,

Blood and Marrow Transplant Handbook

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Mammen Chandy Biology of Blood and Marrow Transplantation

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Addition of Plerixafor to Mobilization Regimens in Autologous Peripheral Blood Stem Cell Transplants Does Not Affect the Correlation of Preharvest Hematopoietic.

Treatment versus Transplant for Challenging Hematologic Disorders

Mary Eapen Biology of Blood and Marrow Transplantation

Hematopoietic Cell Yield Declines Predictably Over Time During Apheresis Allison F. Hazlett, Elaine Wang, Jennifer Anderson, Harold Chung, John Michael.

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Older Age But Not Donor Health Impairs Allogeneic Granulocyte Colony-Stimulating Factor (G-CSF) Peripheral Blood Stem Cell Mobilization Elie Richa, Mona.

In Memoriam: E. Donnall Thomas

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Optimal Donor Selection: Beyond HLA

Donald R. Dengel, Aaron S. Kelly, Lei Zhang, Qi Wang, James S

Radiation Disasters: Role of the BMT Team

Presentation transcript:

A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor Hareth Nahi, Marina Celanovic, Qianying Liu, Johan Lund, Valdas Peceliunas Biology of Blood and Marrow Transplantation Volume 25, Issue 1, Pages 34-40 (January 2019) DOI: 10.1016/j.bbmt.2018.08.020 Copyright © 2018 Terms and Conditions

Figure 1 Study design. Biology of Blood and Marrow Transplantation 2019 25, 34-40DOI: (10.1016/j.bbmt.2018.08.020) Copyright © 2018 Terms and Conditions

Figure 2 Patients with MM cells detected in either apheresis product and/or peripheral blood. AP indicates apheresis product; FUP, follow-up of patients after transplantation; PB, peripheral blood. FUP 1 = 100 days; FUP 2 = 6 months; FUP 3 = 12 months; FUP 4 = 18 months; FUP 5 = 24 months post-transplantation. % of MM cells are expressed among WBCs. Biology of Blood and Marrow Transplantation 2019 25, 34-40DOI: (10.1016/j.bbmt.2018.08.020) Copyright © 2018 Terms and Conditions